Margetuximab
Margenza (margetuximab) is an antibody pharmaceutical. Margetuximab was first approved as Margenza on 2020-12-16. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2.
| Trade Name | Margenza |
|---|---|
| Common Name | Margetuximab |
| Indication | |
| Drug Class | Monoclonal antibodies: chimeric, tumors as target |
